+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ablynx  - logo

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, oncology, and respiratory diseases. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Immunology Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Immunology Collaboration and Licensing Deals 2016-2024

  • Report
  • October 2024
  • 450 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
From
From
From
From
From
Autoimmune Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2024

  • Report
  • October 2024
  • 500 Pages +
  • Global
From
Nanomedicine Global Market Report 2024 - Product Thumbnail Image

Nanomedicine Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1191 Pages
  • Global
From
Vasculitis Treatment - Global Strategic Business Report - Product Thumbnail Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • November 2024
  • 183 Pages
  • Global
From
Monoclonal Antibody Collaboration and Licensing Deals 2019-2024 - Product Thumbnail Image

Monoclonal Antibody Collaboration and Licensing Deals 2019-2024

  • Report
  • November 2024
  • 350 Pages
  • Global
From
From
Loading Indicator